Why GLP-1s May or May Not Be for You

Sanjay Gupta· Host0:00

[upbeat music] Hey there. Welcome to Chasing Life. You know, when Ozempic first hit the market in two thousand seventeen, it was the start of a revolution. The medication, approved to treat type two diabetes, was also helping people lose weight, sometimes a lot of it, and that fact did not go unnoticed. The drug seemed to usher in a paradigm shift in the field of weight management. Other GLP receptor agonists, as they are called, soon followed. Wegovy, Mounjaro, Zepbound. They helped millions of people do what they'd been unable to do before: lose weight seemingly without effort. So demand for them surged, no surprise, and since their widespread use, so has our understanding of them. The landscape has changed a lot since we first reported on these drugs on Chasing Life. So today, we're bringing back my friend and colleague, Meg Tirrell, who has been covering them since the start. She's gonna update us on what is new, what's on the horizon, and let me tell you, there's a lot to talk about. I'm CNN chief medical correspondent, Dr. Sanjay Gupta, and this is Chasing Life.

Speaker 11:08

[upbeat music] Dinner time. It's more than just a meal. It's when work comes to a halt, where macaroni masterpieces are made, and little moments turn into lasting memories. [laughs] With the Blue Cash Preferred card, you can get six percent cash back at US supermarkets, so you can bring home the flavors that bring everyone together.